Rezolute to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rezolute (Nasdaq:RZLT), a late-stage rare disease company focused on treating hypoglycemia from hyperinsulinism, announced participation in two upcoming investor conferences.

Management will join the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the Jefferies Global Healthcare Conference from June 2-4, 2026, for fireside chats and one-on-one meetings.

News Market Reaction – RZLT

-1.25%

9 alerts

-1.25% Session close to close

$319.63M Market Cap

0.6x Rel. Volume

In the May 11 session, RZLT declined 1.25%, reflecting a mild negative market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: H.C. Wainwright 4^th Annual BioConnect Investor Conference
Date: May 19, 2026

Event: Jefferies Global Healthcare Conference
Date: June 2-4, 2026

Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

When will Rezolute (Nasdaq:RZLT) attend the H.C. Wainwright BioConnect Investor Conference in 2026?

Rezolute will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. According to Rezolute, management will join fireside chats and hold one-on-one meetings with investors during the event.

What are the dates of Rezolute (RZLT) participation at the 2026 Jefferies Global Healthcare Conference?

Rezolute will take part in the Jefferies Global Healthcare Conference from June 2-4, 2026. According to Rezolute, management will be available for fireside chats and individual investor meetings across the conference dates.

What type of investor meetings will Rezolute (RZLT) hold at the May and June 2026 conferences?

Rezolute management plans to participate in fireside chats and one-on-one investor meetings at both conferences. According to Rezolute, these formats allow in-depth discussion of its rare disease pipeline and strategy with institutional investors.

How can investors schedule one-on-one meetings with Rezolute (RZLT) at the 2026 investor conferences?

Investors can request meetings with Rezolute management through their H.C. Wainwright or Jefferies representatives. According to Rezolute, outreach should be directed to the respective conference sponsors to coordinate available time slots.

What does Rezolute (RZLT) focus on in its rare disease pipeline for investors?

Rezolute is a late-stage rare disease company targeting hypoglycemia caused by all forms of hyperinsulinism. According to Rezolute, its programs aim to address severe, recurrent low blood sugar in patients with hyperinsulinism (HI).